Modality
mRNA
MOA
BETi
Target
TNFα
Pathway
Tau
TTR AmyloidosisMGEndometrial Ca
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
~Apr 2021
→ ~Jul 2022
Phase 3
Oct 2022
→ Dec 2025
Phase 3Current
NCT07163448
1,972 pts·MG
2022-10→2025-12·Recruiting
1,972 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-268mo agoEnrollment Complete· TTR Amyloidosis
2025-12-044mo agoPh3 Readout· MG
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P3
Recruit…
Catalysts
Enrollment Complete
2025-07-26 · 8mo ago
TTR Amyloidosis
Ph3 Readout
2025-12-04 · 4mo ago
MG
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07163448 | Phase 3 | MG | Recruiting | 1972 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| 369-8021 | Hansoh Pharma | Approved | BTK | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα |